1. Integrating [ 18 F]-Fluorodeoxyglucose Positron Emission Tomography with Computed Tomography with Radiation Therapy and Immunomodulation in Precision Therapy for Solid Tumors.
- Author
-
Prendergast, Conor M., Lopci, Egesta, Seban, Romain-David, De Jong, Dorine, Ammari, Samy, Aneja, Sanjay, Lévy, Antonin, Sajan, Abin, Salvatore, Mary M., Cappacione, Kathleen M., Schwartz, Lawrence H., Deutsch, Eric, and Dercle, Laurent
- Subjects
MEDICAL quality control ,DISEASE progression ,POSITRON emission tomography computed tomography ,IMMUNOMODULATORS ,INDIVIDUALIZED medicine ,IMMUNE system ,TUMOR classification ,MEDICAL protocols ,RADIOPHARMACEUTICALS ,RADIATION doses ,DEOXY sugars ,TUMORS ,IMMUNOTHERAPY - Abstract
Simple Summary: Radiation therapy has long been reported to affect tumors distal to the site of irradiation, in what is known as the abscopal effect; the synergy of radiation with immune-oncological agents has also been studied and exploited for greater anti-cancer effect. We believe that PET/CT imaging can offer insight into the mechanism of this synergy and thereby optimize the dosing and timing as well as monitoring the response to and adverse effects of radiation therapy in tandem with immunotherapy. Herein, we offer a commentary to better integrate PET/CT into recently released joint guidelines, to exploit radiation and immunotherapy synergy. [
18 F]-FDG positron emission tomography with computed tomography (PET/CT) imaging is widely used to enhance the quality of care in patients diagnosed with cancer. Furthermore, it holds the potential to offer insight into the synergic effect of combining radiation therapy (RT) with immuno-oncological (IO) agents. This is achieved by evaluating treatment responses both at the RT and distant tumor sites, thereby encompassing the phenomenon known as the abscopal effect. In this context, PET/CT can play an important role in establishing timelines for RT/IO administration and monitoring responses, including novel patterns such as hyperprogression, oligoprogression, and pseudoprogression, as well as immune-related adverse events. In this commentary, we explore the incremental value of PET/CT to enhance the combination of RT with IO in precision therapy for solid tumors, by offering supplementary insights to recently released joint guidelines. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF